Stefano ButtÃ²

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3970542/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Analysis of HIVâ€1 integrase genotypes and polymorphisms among integrase inhibitorsâ€based antiretroviral treatment naÃ`ve patients in South Sudan. Journal of Medical Virology, 2022, 94, 3320-3327.	5.0	2
2	New insights into pathogenesis point to HIV-1 Tat as a key vaccine target. Archives of Virology, 2021, 166, 2955-2974.	2.1	6
3	Global and regional epidemiology of HIV-1 recombinants in 1990–2015: a systematic review and global survey. Lancet HIV,the, 2020, 7, e772-e781.	4.7	51
4	High HIV-1 diversity in immigrants resident in Italy (2008–2017). Scientific Reports, 2020, 10, 3226.	3.3	8
5	HIV therapeutic vaccines aimed at intensifying combination antiretroviral therapy. Expert Review of Vaccines, 2020, 19, 71-84.	4.4	12
6	Health inequalities: a Research Positioning Exercise at the National Institute of Health, Italy. European Journal of Public Health, 2019, 29, 943-947.	0.3	2
7	Anti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the Disease. Vaccines, 2019, 7, 99.	4.4	14
8	Global and regional molecular epidemiology of HIV-1, 1990–2015: a systematic review, global survey, and trend analysis. Lancet Infectious Diseases, The, 2019, 19, 143-155.	9.1	255
9	"cART intensification by the HIV-1 Tat B clade vaccine: progress to phase III efficacy studies― Expert Review of Vaccines, 2017, 17, 1-12.	4.4	4
10	Correlates of infection and molecular characterization of blood-borne HIV, HCV, and HBV infections in HIV-1 infected inmates in Italy. Medicine (United States), 2016, 95, e5257.	1.0	10
11	HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4+ T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial. Retrovirology, 2016, 13, 34.	2.0	33
12	Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine. Expert Opinion on Biological Therapy, 2015, 15, 13-29.	3.1	19
13	Building up a collaborative network for the surveillance of HIV genetic diversity in Italy. A pilot study. Annali Dell'Istituto Superiore Di Sanita, 2015, 51, 321-6.	0.4	0
14	Molecular Characterization of HIV-1 Subtype C gp-120 Regions Potentially Involved in Virus Adaptive Mechanisms. PLoS ONE, 2014, 9, e95183.	2.5	3
15	A new antigen scanning strategy for monitoring HIV-1 specific T-cell immune responses. Journal of Immunological Methods, 2012, 375, 46-56.	1.4	11
16	HIV-1 Tat Promotes Integrin-Mediated HIV Transmission to Dendritic Cells by Binding Env Spikes and Competes Neutralization by Anti-HIV Antibodies. PLoS ONE, 2012, 7, e48781.	2.5	56
17	Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial. Vaccine, 2011, 29, 5558-5566.	3.8	28
18	A multiplex calibrated real-time PCR assay for quantitation of DNA of EBV-1 and 2. Journal of Virological Methods, 2011, 178, 98-105.	2.1	13

STEFANO BUTTÃ²

#	Article	IF	CITATIONS
19	May Phylogenetic Analysis Support Epidemiological Investigation in Identifying the Source of HIV Infection?. AIDS Research and Human Retroviruses, 2011, 27, 455-457.	1.1	2
20	Performance of V3-based HIV-1 sero subtyping in HIV endemic areas. Annali Dell'Istituto Superiore Di Sanita, 2011, 47, 424-8.	0.4	0
21	Characterization of HIV Type 1 Genetic Diversity Among South African Participants Enrolled in the AIDS Vaccine Integrated Project (AVIP) Study. AIDS Research and Human Retroviruses, 2010, 26, 705-709.	1.1	9
22	Identification of recent HIV infections and of factors associated with virus acquisition among pregnant women in 2004 and 2006 in Swaziland. Journal of Clinical Virology, 2010, 48, 180-183.	3.1	12
23	HIV virology and pathogenetic mechanisms of infection: a brief overview. Annali Dell'Istituto Superiore Di Sanita, 2010, 46, 5-14.	0.4	96
24	The epidemic of HIV infection and AIDS, promotion of testing, and innovative strategies. Annali Dell'Istituto Superiore Di Sanita, 2010, 46, 15-23.	0.4	9
25	Laboratory diagnostics for HIV infection. Annali Dell'Istituto Superiore Di Sanita, 2010, 46, 24-33.	0.4	26
26	Suggested strategies for the laboratory diagnosis of HIV infection in Italy. Annali Dell'Istituto Superiore Di Sanita, 2010, 46, 34-41.	0.4	10
27	Containment of Infection in Tat Vaccinated Monkeys After Rechallenge with a Higher Dose of SHIV89.6P _{cy243} . Viral Immunology, 2009, 22, 117-124.	1.3	18
28	Tat protein vaccination of cynomolgus macaques influences SHIV-89.6Pcy243 epitope variability. Virus Genes, 2008, 36, 105-115.	1.6	3
29	Detection of recent HIV infections in African individuals infected by HIV-1 non-B subtypes using HIV antibody avidity. Journal of Clinical Virology, 2008, 41, 288-292.	3.1	24
30	Cross-clade immune responses to Gag p24 in patients infected with different HIV-1 subtypes and correlation with HLA class I and II alleles. Vaccine, 2008, 26, 5182-5187.	3.8	10
31	Subtype Assignment and Phylogenetic Analysis of HIV Type 1 Strains in Patients from Swaziland. AIDS Research and Human Retroviruses, 2008, 24, 323-325.	1.1	3
32	Building collaborative networks for HIV/AIDS vaccine development: the AVIP experience. Seminars in Immunopathology, 2006, 28, 289-301.	4.0	6
33	Candidate HIV-1 Tat vaccine development: from basic science to clinical trials. Aids, 2006, 20, 2245-2261.	2.2	61
34	Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag. Virology, 2005, 342, 1-12.	2.4	24
35	Preparing for phase II/III HIV vaccine trials in Africa. Microbes and Infection, 2005, 7, 1436-44.	1.9	7
36	The Presence of Antiâ€Tat Antibodies Is Predictive of Longâ€Term Nonprogression to AIDS or Severe Immunodeficiency: Findings in a Cohort of HIVâ€1 Seroconverters. Journal of Infectious Diseases, 2005, 191, 1321-1324.	4.0	118

STEFANO BUTTÃ²

#	Article	IF	CITATIONS
37	Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. Vaccine, 2004, 22, 3258-3269.	3.8	70
38	Genetic and phylogenetic analyses of HIV-1 corroborate the transmission link hypothesis. Journal of Clinical Virology, 2004, 30, 11-18.	3.1	18
39	Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant. European Journal of Immunology, 2003, 33, 1548-1556.	2.9	64
40	SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine. Journal of Medical Primatology, 2003, 29, 193-208.	0.6	51
41	Sequence Conservation and Antibody Crossâ€Recognition of Clade B Human Immunodeficiency Virus (HIV) Type 1 Tat Protein in HIVâ€1–Infected Italians, Ugandans, and South Africans. Journal of Infectious Diseases, 2003, 188, 1171-1180.	4.0	75
42	Human CD38 interferes with HIVâ€1 fusion through a sequence homologous to the V3 loop of the viral envelope glycoprotein gp120 FASEB Journal, 2003, 17, 1-20.	0.5	28
43	HIV-1 Tat-Based Vaccines: From Basic Science to Clinical Trials. DNA and Cell Biology, 2002, 21, 599-610.	1.9	35
44	Calibrated Real-Time PCR Assay for Quantitation of Human Herpesvirus 8 DNA in Biological Fluids. Journal of Clinical Microbiology, 2002, 40, 4652-4658.	3.9	45
45	Micellar-type complexes of tailor-made synthetic block copolymers containing the HIV-1 tat DNA for vaccine application. Vaccine, 2002, 20, 2303-2317.	3.8	28
46	Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). Vaccine, 2001, 19, 2862-2877.	3.8	135
47	Tailor-made core-shell nanospheres for antisense oligonucleotide delivery: IV.Adsorption/release behaviour. Journal of Biomaterials Science, Polymer Edition, 2001, 12, 1339-1357.	3.5	4
48	Complex associates of plasmid DNA and a novel class of block copolymers with PEG and cationic segments as new vectors for gene delivery. Journal of Biomaterials Science, Polymer Edition, 2001, 12, 209-228.	3.5	19
49	Kaposi's sarcoma-associated herpesvirus serology in Europe and Uuganda: Multicentre study with multiple and novel assays. Journal of Medical Virology, 2001, 65, 123-132.	5.0	56
50	A seroprevalence study of human herpesvirus type 8 (HHV8) in eastern and Central Africa and in the Mediterranean area. European Journal of Epidemiology, 2001, 17, 871-876.	5.7	47
51	Activation of Matrix-Metalloproteinase-2 and Membrane-Type-1-Matrix-Metalloproteinase in Endothelial Cells and Induction of Vascular Permeability In Vivo by Human Immunodeficiency Virus-1 Tat Protein and Basic Fibroblast Growth Factor. Molecular Biology of the Cell, 2001, 12, 2934-2946.	2.1	110
52	Kaposi's sarcomaâ€associated herpesvirus serology in Europe and Uuganda: Multicentre study with multiple and novel assays. Journal of Medical Virology, 2001, 65, 123-132.	5.0	3
53	Immune activation in Africa is environmentally-driven and is associated with upregulation of CCR5. Aids, 2000, 14, 2083-2092.	2.2	112
54	Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nature Medicine, 1999. 5. 643-650.	30.7	288

Stefano ButtÃ²

#	Article	IF	CITATIONS
55	Prevalence and determinants of anti-lytic and anti-latent antibodies to human herpesvirus-8 among Italian individuals at risk of sexually and parenterally transmitted infections. , 1998, 77, 361-365.		89
56	Biologic and Molecular Characterization of Producer and Nonproducer Clones from HUT-78 Cells Infected with a Patient HIV Isolate. AIDS Research and Human Retroviruses, 1989, 5, 385-396.	1.1	28
57	Serological survey of human immunodeficiency virus (hiv) in ethiopia. Journal of Medical Virology, 1989, 28, 21-24.	5.0	11
58	Recovery of HIV-related Retroviruses From Italian Patients with AIDS or AIDS-related Complex and from Asymptomatic At-Risk Individuals. Annals of the New York Academy of Sciences, 1987, 511, 390-400.	3.8	29
59	HIVenv glycoprotein shares a cross-reacting epitope with a surface protein present on activated human monocytes and involved in antigen presentation. European Journal of Immunology, 1987, 17, 1793-1798.	2.9	45